Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

CVS Health's new chief executive, David Joyner named former UnitedHealth Group executive Steve Nelson as head of Aetna, CVS's troubled insurance unit. A senior AstraZeneca executive is under detention ...

4️⃣ Drug warning: Compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, have been associated with ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Novo Nordisk's third-quarter sales for Wegovy exceeded expectations, relieving investors concerned about demand slowdown.

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...